



This form must be completed before randomising the patient. Photocopy and send the original immediately to your trials unit:

MRC: RADICALS Data Manager, MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London, WC2B 6NH

CCTG: Clinical Trials Assistant, CCTG, Queen's University, 10 Stuart Street, Kingston, Ontario, K7L 3N6, Canada

Patient's initials Date of birth MRC Patient ID No.

CCTG Patient ID No.

Hospital No: Responsible investigator: Institution:

1 ☐ Does the patient meet the eligibility criteria? ptelig
0 = No
1 = Yes

2 ☐ Was the PSA detectable post-operatively? PSAde1
0 = No (go to question 4)
1 = Yes

3 ☐ Post-operative PSA value psapo1
ng/ml or µg/L

4 ☐ PSA assay sensitivity if undetectable assay1
ng/ml or µg/L

ELIGIBILITY CRITERIA

Main entry criteria

- Patient has undergone radical prostatectomy
- Written informed consent

RT Timing Randomisation

- Post-operative serum PSA ≤0.2 ng/ml
- Ideally more than 4 weeks and less than 22 weeks after radical prostatectomy
- One or more of:
 - pT3/4
 - Gleason 7 - 10 (biopsy or surgical sample)
 - Pre-operative PSA ≥10ng/ml
 - Positive margins

To be eligible, the patient must have a post-operative PSA ≤0.2 ng/ml and the date of the last PSA test must be within 30 days of randomisation. Please confirm the date of the most recent PSA test.

5 ☐ Date of PSA test (within 30 days)
d m y

6 ☐ Planned RT schedule rtsched
1 = 52.5Gy in 20 fractions
2 = 66Gy in 33 fractions
3 = Other (discuss with MRC CTU or NCIC CTG)

7 ☐ Planned RT target rttarg
1 = Prostate bed
2 = Prostate bed and pelvic lymph nodes

Please note: Questions 8 and 9 are no longer applicable as RADICALS-HD is now closed to enrolment.

10 ☐ What hormone treatment would the patient likely receive with radiotherapy? hdrnow
0 = None (go to question 12)
1 = 6 months
2 = 2 years
3 = Not yet decided (go to question 12)
4 = Other duration (please specify) —redacted—

11 ☐ Choice of hormone therapy if planned htchoice
1 = LHRH agonist, e.g. Zoladex, with short course anti-androgen
2 = Bicalutamide monotherapy 150mg/daily e.g. Casodex
3 = LHRH antagonist e.g. Degarelix

12 ☐ Has the patient completed the Quality of Life form? compqol
0 = No (please ensure this is completed before the patient is informed of allocation if given consent to participate)
1 = Yes

To randomise, please call MRC: 020 7670 4777 or CCTG: 613 533 6430

13 ☐ Allocated treatment - RADICALS-RT trtalloa
1 = Early radiotherapy
2 = Deferred radiotherapy

Please note: Question 14 is no longer applicable as RADICALS-HD is now closed to enrolment.

15 MRC Patient ID No. 16 NCIC CTG Patient ID No.

Signed by
(Only MRC authorised person or CCTG investigator)

Date
d m y